S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
S&P 500   3,197.52 (+1.34%)
DOW   26,642.59 (+2.13%)
QQQ   260.37 (+0.71%)
AAPL   388.23 (+1.65%)
MSFT   208.35 (+0.62%)
FB   239.73 (+0.31%)
GOOGL   1,520.86 (+0.57%)
AMZN   3,084.00 (-0.64%)
NVDA   415.08 (+3.23%)
CGC   17.38 (+0.46%)
BABA   248.58 (-1.23%)
MU   49.71 (+0.51%)
GE   6.88 (+2.69%)
TSLA   1,516.80 (+1.32%)
AMD   54.72 (+2.11%)
T   29.96 (+0.64%)
ACB   11.75 (-2.73%)
F   6.36 (+4.78%)
GILD   77.19 (+0.67%)
DIS   118.66 (+2.08%)
NFLX   524.88 (-0.12%)
BAC   24.14 (-0.21%)
BA   179.96 (+2.45%)
Log in

NASDAQ:TBIOTranslate Bio Stock Price, Forecast & News

$18.50
+0.95 (+5.41 %)
(As of 07/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$17.36
Now: $18.50
$18.77
50-Day Range
$14.87
MA: $17.84
$26.66
52-Week Range
$6.80
Now: $18.50
$28.09
Volume4.04 million shs
Average Volume986,371 shs
Market Capitalization$1.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.52
Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. It has a collaboration and license agreement with Sanofi Pasteur Inc. to develop mRNA vaccines for up to five infectious disease pathogens. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 1.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.44 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TBIO
CUSIPN/A
CIKN/A
Phone617-945-7361

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.80 million
Book Value$2.56 per share

Profitability

Net Income$-113,290,000.00
Net Margins-859.22%

Miscellaneous

Employees81
Market Cap$1.16 billion
Next Earnings Date7/29/2020 (Estimated)
OptionableNot Optionable

Receive TBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for TBIO and its competitors with MarketBeat's FREE daily newsletter.

Translate Bio (NASDAQ:TBIO) Frequently Asked Questions

How has Translate Bio's stock been impacted by COVID-19 (Coronavirus)?

Translate Bio's stock was trading at $7.43 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TBIO stock has increased by 149.0% and is now trading at $18.50. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Translate Bio?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Translate Bio.

When is Translate Bio's next earnings date?

Translate Bio is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Translate Bio.

How were Translate Bio's earnings last quarter?

Translate Bio Inc (NASDAQ:TBIO) posted its quarterly earnings results on Thursday, May, 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.44) by $0.20. The business earned $4.65 million during the quarter, compared to analyst estimates of $2.23 million. Translate Bio had a negative net margin of 859.22% and a negative return on equity of 63.61%. View Translate Bio's earnings history.

What price target have analysts set for TBIO?

7 analysts have issued twelve-month price objectives for Translate Bio's stock. Their forecasts range from $29.00 to $40.00. On average, they expect Translate Bio's stock price to reach $32.67 in the next twelve months. This suggests a possible upside of 76.6% from the stock's current price. View analysts' price targets for Translate Bio.

What are Wall Street analysts saying about Translate Bio stock?

Here are some recent quotes from research analysts about Translate Bio stock:
  • 1. According to Zacks Investment Research, "Translate Bio, Inc. operates as a therapeutics company. It develops transformative medicines for the treatment of diseases caused by protein and gene dysfunction. Translate Bio, Inc. is based in MA, United States. " (7/1/2020)
  • 2. HC Wainwright analysts commented, "Valuation and risks to achievement of target price. Our price target of $21/share is based on an equally-weighted composite of: (a) $16.9/share, as a 35x multiple of taxed and diluted $4.33 discounted back to FY19 at 18% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $25.6/ share (discounted cash flow analysis using a 12% discount rate and 3.5% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (8/1/2019)

Has Translate Bio been receiving favorable news coverage?

News headlines about TBIO stock have been trending somewhat negative this week, InfoTrie reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Translate Bio earned a news impact score of -1.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Translate Bio.

Are investors shorting Translate Bio?

Translate Bio saw a decline in short interest in June. As of June 15th, there was short interest totaling 1,840,000 shares, a decline of 28.1% from the May 31st total of 2,560,000 shares. Based on an average daily trading volume, of 665,600 shares, the days-to-cover ratio is presently 2.8 days. Approximately 4.4% of the shares of the stock are short sold. View Translate Bio's Current Options Chain.

Who are some of Translate Bio's key competitors?

What other stocks do shareholders of Translate Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Translate Bio investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Regeneron Pharmaceuticals (REGN), Johnson & Johnson (JNJ), Moderna (MRNA), NVIDIA (NVDA), AbbVie (ABBV), Tesla (TSLA) and Carnival (CCL).

Who are Translate Bio's key executives?

Translate Bio's management team includes the following people:
  • Mr. Ronald C. Renaud Jr., Pres, CEO & Director (Age 50)
  • Dr. Michael W. Heartlein, Chief Technology Officer (Age 60)
  • Mr. John R. Schroer C.F.A., CFA, CFO & Treasurer (Age 54)
  • Dr. Richard Wooster, Chief Scientific Officer (Age 59)
  • Mr. Paul D. Burgess J.D., Chief Legal Officer & Corp. Sec. (Age 45)

When did Translate Bio IPO?

(TBIO) raised $100 million in an IPO on Thursday, June 28th 2018. The company issued 7,700,000 shares at a price of $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI acted as the underwriters for the IPO.

What is Translate Bio's stock symbol?

Translate Bio trades on the NASDAQ under the ticker symbol "TBIO."

How do I buy shares of Translate Bio?

Shares of TBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Translate Bio's stock price today?

One share of TBIO stock can currently be purchased for approximately $18.50.

How big of a company is Translate Bio?

Translate Bio has a market capitalization of $1.16 billion and generates $7.80 million in revenue each year. The company earns $-113,290,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Translate Bio employs 81 workers across the globe.

What is Translate Bio's official website?

The official website for Translate Bio is www.translate.bio.

How can I contact Translate Bio?

Translate Bio's mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-945-7361.

This page was last updated on 7/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.